THE PRESENT INVENTION RELATES TO A NOVEL POLYMORPHIC FORM OF ROTIGOTINE CHARACTERIZED BY AT LEAST ONE OF THE FOLLOWING X-RAY POWDER DIFFRACTION PEAKS: 12.04, 13.68,17.72 AND 19.01 ±0.2 (°2θ), MEASURED WITH A CU-KA IRRADIATION (1.54060 Å), AND A PROCESS FOR PRODUCTION THEREOF WHICH IS USEFUL FOR THE MANUFACTURE OF A STABLE MEDICAMENT FOR TREATING OR ALLEVIATING SYMPTOMS OF PARKINSON’S DISEASE AND OTHER DOPAMINE-RELATED DISORDERS. FIGURE 1.